Are Cancer drug prices a reflection of the rising costs of drug development and business risks, or are they a reflection of the industry’s greed- charging whatever they think they can get away with? This article takes a look at the latest new drug for lung cancer, Novartis’ Zykadia, and its older competitor, Pfizer’s Xalkori, and tries to make sense of the price difference. Read more here. (Source: Matthew Herper, Forbes, 8/13/14).
You are here: / / Cancer: Unpronounceable Drugs, Incomprehensible Prices